{"disease":{"id":"her2-positive-solid-tumors","name":"her2 positive solid tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07030569","title":"RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT03219268","title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT04278144","title":"A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":175,"lead_sponsor_name":"Bolt Biotherapeutics, Inc.","has_results":false},{"nct_id":"NCT05245058","title":"SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Shanghai Pharmaceuticals Holding Co., Ltd","has_results":false},{"nct_id":"NCT04257110","title":"A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Bliss Biopharmaceutical (Hangzhou) Co., Ltd","has_results":false},{"nct_id":"NCT04521179","title":"Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT06806982","title":"A Study of VRN101099 in Patients With HER2-Positive Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Voronoi, Inc","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT03319459","title":"FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT04501770","title":"A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Wuhan YZY Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT04189211","title":"A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Bio-Thera Solutions","has_results":false},{"nct_id":"NCT05681650","title":"HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06658951","title":"Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"UTC Therapeutics Inc.","has_results":false},{"nct_id":"NCT05810103","title":"A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}